Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nextbiomedical CoXKRX:389650 +1.82%38 EBITDA Margin % is -8.85% as of Jun. 2026. GuruFocus rates XKRX:389650 with a GF Score™ of 38/100. The stock has 1 warning sign investors should review. Among 942 Biotechnology companies, Nextbiomedical Co ranks better than 68.9% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nextbiomedical Co's EBITDA for the
three
months ended in Jun. 2026 was ₩-437 Mil. Nextbiomedical Co's Revenue for the
three
months ended in Jun. 2026 was ₩4,936 Mil. Therefore, Nextbiomedical Co's EBITDA margin for the quarter that ended in Jun. 2026 was -8.85%.
Nextbiomedical Co (XKRX:389650) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nextbiomedical Co EBITDA Margin % Related Terms
Nextbiomedical Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nextbiomedical Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:389650 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Nextbiomedical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nextbiomedical Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nextbiomedical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nextbiomedical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nextbiomedical Co (XKRX:389650) has a EBITDA Margin % of -8.85% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nextbiomedical Co and its competitors. According to the industry distribution chart, Nextbiomedical Co ranks #293 out of 942 companies in the Biotechnology industry, placing it in the top 31.1%.
Is Nextbiomedical Co's EBITDA Margin % too high?
Nextbiomedical Co's current EBITDA Margin % is -8.85%. Based on the distribution chart, Nextbiomedical Co ranks #293 out of 942 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nextbiomedical Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Nextbiomedical Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nextbiomedical Co ranks #293 out of 942 companies for EBITDA Margin %. This puts Nextbiomedical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nextbiomedical Co and its competitors. Nextbiomedical Co's current EBITDA Margin % is -8.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nextbiomedical Co stock overvalued right now?
Nextbiomedical Co (XKRX:389650) has a current EBITDA Margin % of -8.85%. The current EBITDA Margin % is -8.85%. Nextbiomedical Co's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nextbiomedical Co (XKRX:389650), the current EBITDA Margin % is -8.85% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.
38GF Score
Get the complete analysis for XKRX:389650
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:389650 has been successfully added to your 
